GlassScriptPhysician profile
Chirag M Patel
NPI 1790741312
$7,962.55
in general payments reported to CMS, 2019-2025
32 companies · $997 in 2025
The $997 reported for 2025 was less than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,281 · 2020: $2,026 · 2021: $784 · 2022: $848 · 2023: $896 · 2024: $1,131 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,004 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,003.74 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,747.44 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $1,381.15 | 2019-2025 | |
| Abbvie INC. | $1,166.82 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $505.18 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $363.51 | 2024-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $246.06 | 2024-2025 | Rezdiffra, Resmetirom |
| Intra-Sana Laboratories | $190.01 | 2022-2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Novo Nordisk INC | $186.67 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $147.31 | 2019-2022 | |
| Grifols USA, LLC | $143.91 | 2019-2021 | |
| Orphalan INC | $132.36 | 2024-2025 | Cuvrior |
| Sunovion Pharmaceuticals INC. | $98.94 | 2019 | |
| Mallinckrodt Hospital Products INC. | $89.81 | 2024 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $88.07 | 2019-2021 | |
| Echosens North America, INC. | $60.95 | 2024-2025 | Fibroscan, Fibroscan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $56.29 | 2019 | |
| Dynavax Technologies Corporation | $49.18 | 2019-2023 | Heplisav-B |
| Acorda Therapeutics, INC | $41.58 | 2019 | |
| Merck Sharp & Dohme LLC | $35.90 | 2019-2020 | |
| Lilly USA, LLC | $35.57 | 2023-2024 | Zepbound, Mounjaro |
| Allergan, INC. | $27.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.68 | 2020 | |
| Supernus Pharmaceuticals, INC. | $27.39 | 2019 | |
| Eisai INC. | $27.03 | 2024 | |
| Ironwood Pharmaceuticals, INC | $19.97 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.83 | 2019 | |
| Atricure, INC. | $17.35 | 2020 | |
| Amarin Pharma, INC. | $16.93 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.84 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chirag Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.